AMBP and type 2 diabetes mellitus: T2D patients with elevated Uristatin (>7.5 mg/L) and CV patients with elevated Bikunin (>1.4 μg/mL) were both more likely to progress to comorbidities with significant odds ratios of 13.11 and 4.44, respectively (Table 4–B).